OncoSec to Present at Scientific and Investment Conferences in October

SAN DIEGO, Oct. 10, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at several high-profile events in October, including:  the 15^th Annual BIO Investor Forum and the Annual Sofinnova Japan Biopharma Partnering Conference.

15^th Annual BIO Investor Forum
OncoSec's CEO, Mr. Punit Dhillon, will present a corporate overview at the 15^th Annual BIO Investor Forum on October 19, 2016, at 11:00 AM PDT.  This event will take place at the Westin St. Francis Hotel, in San Francisco, California. To view the live webcast, please access the following link at the time of the presentation: https://www.veracast.com/webcasts/bio/investorforum2016/79213115151.cfm. An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com.

This conference provides a forum for venture-stage growth and emerging public companies to explore investment trends and opportunities in life sciences. For more information, please visit: https://www.bio.org/events/bio-investor-forum.

Annual Sofinnova Japan Biopharma Partnering Conference
Mr. Dhillon will present a corporate overview at the Annual Sofinnova Japan Biopharma Partnering Conference on October 25^th at 10:15 AM JST at the Conrad Hilton in Tokyo, Japan.

This conference brings together premier biotechnology companies from North America and Europe with influential Japanese licensing and business development executives.  For more information, please visit: http://www.sofinnovajapanpartnering.com/.

Biomarkers and Precision Medicine USA Congress
In addition, Robert Pierce, MD, Chief Scientific Strategist and Adil Daud, MD, Chief Clinical Strategist at OncoSec, were both invited as speakers and presenters for the Annual Biomarkers & Precision Medicine USA Congress that was held in San Diego, CA from October 3-4, 2016.

Robert Pierce, MD, presented on "Biomarker Development for Intratumoral Gene Therapy with DNA-encoded IL-12" that focused on the following topics:

• Patient selection biomarkers for low TIL/low anti-PD1 responder population
• Pharmacodynamic (PD) biomarkers of effective in-situ vaccination

Adil Daud, MD, led a panel discussion with Dr. Pierce as a panelist on "Immuno-Oncology Biomarker Development" focusing on the following topics:

• Challenges in Precision medicine;
• Status of PDL1 assay and biomarker development and other pathways;
• Non Respondence of PDL1; and
• Lessons learnt

Dr. Daud also led a presentation on "Biomarker Strategy To Guide Clinical Development Of Cancer Immunotherapy."

OncoSec expects to provide further insights from these scientific presentations in upcoming communications.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer.  ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several indications, including metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT:
Sophia Ononye, PhD MPH MBA
Associate Director, Investor Relations and Corporate Communications
OncoSec Medical Incorporated
855-662-6732
[email protected]

Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO

SOURCE OncoSec Medical Incorporated

Related Links

http://www.oncosec.com